HeartSciences (HSCS) did not report any revenue during Q3 FY2025, and the company's financials as of January 31, 2025, showed cash and cash equivalents of approximately $2.6 million and shareholders’ equity of approximately $1.8 million1. Therefore, it is not accurate to discuss the surge of operating expenses for HSCS in Q3 2025.